Durect corporation announces last patient last visit in phase 2b ahfirm trial of larsucosterol in alcohol-associated hepatitis

Company on track to report topline data from ahfirm in q4 2023 cupertino, calif. , sept. 7, 2023 /prnewswire/ -- durect corporation (nasdaq: drrx), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the last patient has completed the study protocol in the company's ahfirm trial.
DRRX Ratings Summary
DRRX Quant Ranking